Medical/Pharmaceuticals
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
MELBOURNE, Australia, Dec. 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imag...
2023-12-07 06:45
1417
World Innovation Summit for Health Announces Dates for 2024 Event and Strategic Partnership with WHO
Health leaders to prepare report on the protection of health in armed conflict. DOHA, Qatar, Dec. 7, 2023 /PRNewswire/ -- The World Innovation Summit for Health (WISH), an initiative of Qatar Foundation for Education, Science and Community Development (QF), announced the WISH 2024 summit will ta...
2023-12-07 03:00
1755
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
ANDERNACH, Germany, Dec. 6, 2023 /PRNewswire/ -- LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), ...
2023-12-06 23:00
1501
GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant
Starts undertaking quality evaluation and characterization of iPSCs in
accordance with ISO standards
PALO ALTO, Calif., Dec. 6, 2023 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://www.ipeace.com
2023-12-06 22:30
1196
Micro Medical Solutions Announces Completion of Enrollment in the STAND Pivotal Clinical Trial
Clinical investigators complete enrollment in the 177 patient, randomized, controlled study, STAND (A Clinical Evaluation of the MicroSTent PeripherAl Vascular SteNt in subjects with Arterial Disease Below the Knee, NCT03477604). WILMINGTON, Mass., Dec. 6, 2023 /PRNewswire/ -- Micro Medical Solut...
2023-12-06 21:32
1612
SaniSure earns EcoVadis Silver Rating, recognizing strong commitment to sustainability
CAMARILLO, Calif., Dec. 6, 2023 /PRNewswire/ -- SaniSure, a global player in single-use bioprocessing solutions (drug substance and drug product form & fill) and cell & gene therapy is proud to announce that it has been awarded the EcoVadis Silver Rating for its sustainability practices. This rec...
2023-12-06 20:30
1700
WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader
SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced it has successfully passed an on-site GMP audit by a global vaccine leader at its first standalone CDMO site in Suzhou,China. The audit m...
2023-12-06 17:00
1327
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
* XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. * XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland ofChina, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. SHANGHAI AND HONG ...
2023-12-06 17:00
1671
Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%
JINAN, China, Dec. 6, 2023 /PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster pr...
2023-12-06 16:55
1704
Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas
KUALA LUMPUR, Malaysia, Dec. 6, 2023 /PRNewswire/ -- AstraZeneca's Koselugo (selumetinib)is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas...
2023-12-06 16:46
1617
The Grand Opening of River Cam Dermatology Centre and River Cam Nutrition Center (Shatin) Amalgamates Ancient Chinese Medicine Skin Care Wisdom and Nutrition Science
HONG KONG, Dec. 6, 2023 /PRNewswire/ -- River Cam Medical Group announced the grand opening of the River Cam Dermatology Centre and River Cam Nutrition Centre (the Centre) on 29th November 2023. Located on the 7th Floor, Citylink Plaza, Shatin,Hong Kong, the Centre boasts a facial acupuncture tre...
2023-12-06 10:43
1390
GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
* To commence operation by 2027…with max. 400K liters of plasma production capacity per annum * The first step towards localization of Indonesia's critical medical product YONGIN,South Korea, Dec. 5, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced onDece...
2023-12-06 08:56
1427
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-12-06 08:16
3149
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 6, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeuti...
2023-12-06 01:01
1731
The 2023 Investor Open Day of Zylox-Tonbridge was successfully held
HANGZHOU, China, Dec. 5, 2023 /PRNewswire/ -- On November 29th, the 2023 Investor Open Day of Zylox-Tonbridge ("2190. HK", hereinafter referred to as "the Company") was successfully held in Hangzhou, China. The event attracted more than 200 online and offline investors and securities analysts wo...
2023-12-05 22:22
3817
inQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America
WINCHESTER, Mass. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ -- inQB8 Medical Technologies LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)),announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve (TTV) in a patient suffering from torrenti...
2023-12-05 21:00
1330
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...
2023-12-05 21:00
1113
Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis
* Combines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies * Virtually screens compounds from a universe of >60 billion chemical targets and evaluates synthesis routes for safer, cost-effective, higher-yield drug manufactu...
2023-12-05 21:00
1374
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects --The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obtained the approval from Institutional Review Board of Hu...
2023-12-05 16:50
1526
J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023
SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that
early results of the Phase 1/2 study of its novel, orally administered 4th
generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference
held inSingapore from 1st to 3rd December 2023.
2023-12-05 15:16
1190
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
7889
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
6989
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
2024-04-24 13:00
4283
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2919